

Management of Urology

Series Editors: Sanchia S. Goonewardene · Raj Persad

Sanchia S. Goonewardene

Karen Ventii · Amit Bahl · Raj Persad

Hanif Motiwala · David Albala

Management of Muscle Invasive Bladder Cancer



Springer

Management of Urology

Series Editors

Sanchia S. Goonewardene

Southend University Hospital NHS Foundation Trust
Southend, UK

Raj Persad

North Bristol NHS Trust
Bristol, UK

This series addresses the need for an increase in the quantity of literature focused upon the management in urology. Books within it will draw attention to the management of subtype specific urology. Therefore, it is of interest to a range of trainee and practicing physicians in a range of disciplines including urology, oncology, specialist nurse and general practitioners.

More information about this series at <http://www.springer.com/series/16626>

Sanchia S. Goonewardene • Karen Ventii
Amit Bahl • Raj Persad • Hanif Motiwala
David Albala

Management of Muscle Invasive Bladder Cancer

Sanchia S. Goonewardene
Southend University Hospital NHS
Foundation Trust
Southend
UK

Amit Bahl
North Bristol NHS Trust
Bristol
UK

Hanif Motiwala
Southend University Hospital
Westcliff-on-Sea
UK

Karen Ventii
Harvard University
Boston, MA
USA

Raj Persad
North Bristol NHS Trust
Bristol
UK

David Albala
Fayetteville, NY
USA

ISSN 2730-6372
Management of Urology
ISBN 978-3-030-57914-2
<https://doi.org/10.1007/978-3-030-57915-9>

ISSN 2730-6380 (electronic)
ISBN 978-3-030-57915-9 (eBook)

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gärberstrasse 11, 6330 Cham, Switzerland

Preface

Welcome to Management of Muscle Invasive Bladder Cancer (NMIBC). The concept of this book first came to me as a young trainee, whilst assisting with cystectomies. I had often read papers, but very rarely understood controversies in management of muscle invasive bladder cancer.

Bladder cancer has considerable impact on patients. It presents aggressively, very often, already having advanced into muscle. The patient pathway is very often prolonged and, due to the nature of disease, has poor outcomes.

Bladder cancer is often considered the ‘Cinderella’ of all the cancers—under-funded for research. The aim of this book is to use the knowledge to further develop your practice and improve patient care. It has been a pleasure to put this together for you.

Southend, UK

Sanchia S. Goonewardene

Acknowledgements

For my family and friends—always supporting me in what I do.

For all the superheroes in my life—you are truly inspirational.

For my team at Springer Nature, for always giving me a chance to get published.

For Dr. Ventii, a true friend and colleague.

For Prof Persad—my mentor for the past 7 years, thank you.

For Prof Motiwala—former TPD and Chief Examiner, FRCS Urol, a visionary in the urology field.

For Prof Albala—My Editor In Chief, friend and mentor—generally awesome.

For my TPD, Ms Georgina Wilson, for always supporting me and my academic endeavours.

Contents

Part I Introduction

1	Introduction to Muscle Invasive Bladder Cancer	3
	References	4

Part II Epidemiology and the Molecular Basis of Bladder Cancer

2	Epidemiology and Risk Factors in Muscle Invasive Bladder Cancer	7
2.1	Research Methods	7
2.2	Flavonoids and Bladder Cancer Risk	9
2.3	Metabolic Factors and Risk of Bladder Cancer	9
2.4	Smoking Cessation and Bladder Cancer Risk	9
2.5	Occupational Exposure in Muscle Invasive Bladder Cancer	10
2.6	Androgen Suppression Therapy and Risk of Muscle Invasive Bladder Cancer	11
2.7	Reviews Associated with Epidemiology and Risk Factors in Bladder Cancer	11
	References	11
3	Epidemiology, Risk Factors and Occupational Hazards	13
3.1	Systematic Review Results on Bladder Cancer Epidemiology, Occupational Hazards and Risk Factors	15
3.1.1	Bladder Cancer Survival	15
3.1.2	Carcinogenic Agents: Population Studies	15
3.1.3	Populations Studies with Women	15
3.1.4	Population Studies with Men	16
3.1.5	Arylamines	16
3.1.6	Anilene Dyes	17
3.1.7	Arsenic	17
3.1.8	Textile Industry	17
3.1.9	Metalworking Fluids Exposure	18
3.1.10	Smoking and Bladder Cancer	18
3.1.11	Impact of Occupational Risk Factors on Prognosis of Recurrent Bladder Cancer	19

3.1.12	Results from the Literature and Other Reviews on Bladder Cancer Epidemiology, Risk Factors, Occupational Exposure	19
References		20
4	The Molecular Basis of Muscle Invasive Bladder Cancer	23
4.1	Research Methods	23
4.2	Systematic Review Results	25
4.2.1	The Molecular Basis of Bladder Cancer: Precision Diagnostics and Treatment	25
4.2.2	PIK3CA Mutations in Muscle Invasive Bladder Cancer	25
4.2.3	Epidermal Growth Factor in Muscle Invasive Bladder Cancer	25
4.2.4	P53, pRB and RAS in Muscle Invasive Bladder Cancer	26
4.2.5	Transcriptome Profiling in Muscle Invasive Bladder Cancer	26
4.2.6	Methylation Status in Bladder Cancer	26
4.2.7	The Cancer Genome Project and the Molecular Basis of Bladder Cancer	26
References		27

Part III Management of Histological Variants

5	Histological Variants in MIBC: Squamous Cell and Squamous Differentiation	31
5.1	Risk Factors	31
5.2	Survival Outcomes	32
5.3	Squamous Cell and Evidence of Metastatic Disease	32
References		33
6	Histological Variants in Muscle Invasive Bladder Cancer: Adenocarcinoma	35
6.1	Survival Outcomes in Bladder Adenocarcinoma: Radical Surgery vs. Resection	35
6.2	CEA and CA 19-9 in Diagnostics in Muscle Invasive Adenocarcinoma of the Bladder	36
6.3	Muscle Invasive Adenocarcinoma of the Bladder Mimicking a Ureterocoele	37
6.4	Partial Cystectomy and Radiotherapy in Adenocarcinoma of the Bladder	37
6.5	Neoadjuvant Chemotherapy in Bladder Adenocarcinoma	37
6.6	Adjuvant Therapy in Adenocarcinoma of the Bladder	38
6.7	Novel Chemotherapeutic Agents for Metastatic Adenocarcinoma of the Bladder	38
6.8	Systematic Reviews Related: Lymphadenectomy in Adenocarcinoma of the Bladder	38
References		39

7	Histological Variants in Muscle Invasive Bladder Cancer:	
	Sarcomatoid Cancer	41
7.1	Causes of Sarcomatoid Bladder Cancer.	41
7.2	Diagnostics in Sarcomatoid Bladder Cancer	42
7.3	Clinicopathological and Immunohistochemical Diagnosis of Sarcomatoid Bladder Cancer	42
7.4	Survival Outcomes with Radical Cystectomy and Sarcomatoid Carcinoma	43
7.5	Adjuvant Chemotherapy in Sarcomatoid Bladder Cancer.....	43
	References.....	44
8	MIBC Carcinosarcoma	45
8.1	The Genetic Basis of Carcinosarcoma.....	45
8.2	Histopathology of Carcinosarcoma	46
8.3	Clinical Presentation of Carcinosarcoma.....	48
8.4	Survival Outcomes.....	48
8.5	Surgical Treatment for Carcinosarcoma	49
8.6	Adjuvant Therapy in Carcinosarcoma	49
8.7	Neoadjuvant Chemotherapy in Carcinosarcoma	50
	References.....	51
9	Muscle Invasive Bladder Cancer: Small Cell	53
9.1	Neuroendocrine Markers in Small Cell Bladder Cancer	53
9.2	Cytological and Immunological Analyses in Small Cell Bladder Carcinoma.....	53
9.3	Survival Outcomes.....	54
9.4	Prognostic Factors in Diagnosis of Small Cell Bladder Cancer	54
9.5	Clinical Presentation of Small Cell Bladder Cancer	55
9.6	Surgical Outcomes.....	56
9.7	Neoadjuvant Chemotherapy in Small Cell Bladder Cancer.....	57
9.8	Radiotherapy in Small Cell Cancer of the Bladder	58
9.9	Adjuvant Therapy in Small Cell Cancer of the Bladder	58
9.10	Chemotherapy and Radiotherapy in Metastatic Small Cell Carcinoma of the Bladder	59
	References.....	60
10	MIBC Plasmacytoid Bladder Cancer	63
10.1	Clinical Presentation of Plasmacytoid Bladder Cancer.....	63
10.2	Immunohistochemical Diagnosis in Plasmacytoid Cancer	63
10.3	Survival Outcomes.....	64
10.4	Surgical Outcomes in Plasmacytoid Bladder Cancer	65
10.5	Patterns of Metastases: Plasmacytoid Bladder carcinoma	66
10.6	Neoadjuvant Chemotherapy in Plasmacytoid Bladder Cancer	66
10.7	Recurrence in Plasmacytoid Bladder Cancer.....	67
	References.....	68

11 MIBC and Micropapillary Bladder Cancer	71
11.1 Histopathology of Micropapillary Bladder Carcinoma	71
11.2 Clinical Presentation of Micropapillary Bladder Cancer	72
11.3 Clinical Risk Stratification in Micropapillary Bladder Cancer	73
11.4 Survival Outcomes in Micropapillary Bladder Cancer	73
11.5 Neoadjuvant Chemotherapy in Micropapillary Bladder Cancer	74
11.6 Trimodal Therapy in Micropapillary Bladder Cancer	74
11.7 Surgical Outcomes in Micropapillary Bladder Cancer	74
11.8 Adjuvant Therapy in Micropapillary Bladder Cancer	76
References	76

Part IV Assessment and Diagnosis in MIBC

12 MIBC Bladder Cancer Assessment and Diagnosis	81
12.1 Clinical Presentation of Bladder Cancer	81
12.2 Diagnosis and Assessment in Bladder Cancer	82
12.3 The Role of Haematuria Clinics in Bladder Cancer	83
12.4 Bladder Cancer Screening	84
12.5 Biomarkers in Bladder Cancer Diagnostics	84
12.6 Guidelines and Diagnostics in Bladder Cancer	85
12.7 Diagnostic Imaging in Bladder Cancer	85
12.8 Novel Methods for Diagnosis of Bladder Cancer	86
12.9 Gender Discrepancies in Bladder Cancer Diagnostics	87
References	88
13 Bladder Cancer Screening	91
13.1 Systematic Review Results	92
13.1.1 Urinary Metabolomes in Bladder Cancer Screening	92
13.1.2 CellDetect in Bladder Cancer Screening	93
13.1.3 Blue Light Flexible Cystoscopy	93
13.1.4 Bladder Epicheck in Bladder Cancer Screening	97
13.1.5 Urinary miRNA-96 in Bladder Cancer Diagnosis	97
13.1.6 Urinary Cytology in Bladder Cancer Screening	97
13.1.7 Porphyrins as Urinary Biomarkers	98
13.1.8 Quantitative mRNA Determination in Bladder Cancer Screening	98
13.1.9 Biomarkers in Bladder Cancer Screening	98
13.1.10 Cytokeratin 20 and IGF2 in Bladder Cancer Screening	99
13.1.11 Angiogenin and Clusterin in Urinary Cytology in Bladder Cancer Screening	99
13.1.12 Methylation and Line 1 in Bladder Cancer Screening	99
13.1.13 Metabolomic Urinary Profiles in Bladder Cancer Screening	100
13.1.14 Mitochondrial DNA in Bladder Cancer Screening	100

13.1.15	Tyr-Phosphorylated Proteins in Bladder Cancer Screening	100
13.1.16	GC-Globulin in Bladder Cancer Screening	101
13.1.17	Methylation Status with p16 and p14 in Bladder Cancer Screening	101
13.1.18	Urine Tumour Associated Trypsin Inhibitor.....	101
13.1.19	mRNA in Bladder Cancer Screening	102
13.1.20	Urinary Basic Fetoprotein and BTA Test in Urinary Cytology	102
13.1.21	BTA Stat Test vs. NMP 22 vs. Urine Cytology	102
13.1.22	NMP 22 as a Screening Test in Bladder Cancer.	103
13.1.23	Urinary Fibrin as a Screening Test for Bladder Cancer ..	103
13.1.24	DNA Image Cytometry in Bladder Cancer Screening ..	104
13.1.25	Matrix Metalloproteinases in Bladder Cancer Screening..	104
13.1.26	Microsatellite Markers in Bladder Cancer Screening.....	104
13.1.27	Conclusion	105
	References.....	105
14	A Systematic Review on Blue Light Cystoscopy in Bladder Cancer Diagnostics	109
14.1	Systematic Review Methods	109
14.2	Systematic Review Results	110
14.2.1	Blue Light vs. White Light Cystoscopy	110
14.2.2	Efficacy and Safety of Blue Light vs. White Light in Bladder Cancer Diagnostics	111
14.2.3	Blue Light Cystoscopy and Early Detection of Bladder Cancer.....	112
14.2.4	Blue Light Cystoscopy and Malignant vs. Benign Lesions	113
14.2.5	Role of Blue Light Cystoscopy in Detection of CIS	114
14.2.6	Blue Light Cystoscopy in Atypical Bladder Cancer Diagnosis	114
14.2.7	Role of Blue Light Cystoscopy in Positive Cytology.....	114
14.2.8	Blue Light Cystoscopy and Role in Bladder Cancer Surveillance	115
14.2.9	Blue Light Cystoscopy in Detection of Recurrence.....	115
14.2.10	Blue Light Cystoscopy in High Risk Patients	116
14.2.11	Blue Light Cystoscopy in Progression of Bladder Cancer.....	116
14.2.12	Accuracy of Blue vs. White Light Cystoscopy	116
14.2.13	Reviews Related to Systematic Review	118
14.2.14	Grey Literature Related to Systematic Review.....	118
14.2.15	Conclusions	118
	References.....	118

15 Muscle Invasive Bladder Cancer and the Staging Conundrum: Which Imaging Modality Is Best?	121
15.1 MRI in Bladder Cancer	121
15.2 PET Imaging in Bladder Cancer	123
References	125
16 A Systematic Review on the Staging Conundrum in Bladder Cancer	127
16.1 Systematic Review Results	128
16.1.1 Variation in Imaging for Bladder Cancer Staging	128
16.1.2 MRI in Detection of NMIBC vs. MIBC	129
16.1.3 MRI in Low Grade vs. High Grade Bladder Cancer	129
16.1.4 Sensitivity and Specificity of MRI vs. CT Urogram	130
16.1.5 The Role of High Resolution Ultrasound in Bladder Cancer Staging	130
16.1.6 Staging and VIRADS	130
16.1.7 The Role of FDG PET in Bladder Cancer Staging	131
16.1.8 Reviews Related to Systematic Review	131
16.1.9 Grey Literature Related to Systematic Review	132
16.1.10 Systematic Review Conclusion	132
References	132
17 Current State of Investigations and Limitations in Muscle Invasive Bladder Cancer	135
17.1 MIBC: Is Upper Tract Imaging Required?	135
17.2 MIBC: Is There a Role for Urine Cytology in Haematuria Investigations?	135
17.3 Is Cystoscopy Required for Investigation of Microscopic Haematuria?	136
17.4 Role of Biomarkers as a Replacement for Haematuria Investigations	136
References	137
18 Bladder Cancer Surveillance	139
18.1 Research Methods	139
18.2 Systematic Review Results	141
18.2.1 Urinary Metabolites in Bladder Cancer Surveillance	141
18.2.2 CellDetect in Bladder Cancer Surveillance	141
18.2.3 NMP 22 in Bladder Cancer Surveillance	142
18.2.4 5-Aminolevulinic Acid-Induced Fluorescence Endoscopy in Bladder Cancer Surveillance	142
18.2.5 The BTA Stat Test in Bladder Cancer Surveillance	143
18.2.6 Bladder EpiCheck in Bladder Cancer Surveillance	143
18.2.7 Microsatellite Analysis in Bladder Cancer Surveillance	143
18.2.8 Urinary Cytology, BTA Trak and Cytokeratin's 8 and 18	144
18.2.9 Urotel in Bladder Cancer Surveillance	144
References	144

19 Risk Stratification in Bladder Cancer	147
19.1 Accuracy of EORTC Risk Stratification	147
19.2 EORTC Risk Stratification for MIBC Post Radical Cystectomy	147
19.3 EORTC/CUETO Risk Stratification in Second TURBT	148
19.4 Accuracy of EORTC and CUETO Scoring Systems	148
19.5 EORTC vs. EAU Risk Stratification	149
19.6 Assessment of BCG Therapy Using the CUETO Risk Stratification Model	150
19.7 AUA/SUO Guidelines in Bladder Cancer	150
19.8 EORTC Classification vs. AUA Guidelines for Bladder Cancer	150
References	151
20 Risk Prediction and Nomograms in Bladder Cancer	153
20.1 Systematic Review Results	155
20.1.1 Molecular Markers in Bladder Cancer Risk	155
20.1.2 Preoperative Factors Predicting Risk	155
20.1.3 Prediction of Lymph Node Metastasis	155
20.1.4 Nomogram to Predict Survival in Bladder Cancer	156
20.1.5 Prediction of Recurrence Risk	157
20.1.6 Postoperative Factors Affecting Survival	158
20.1.7 Recurrence After Radical Cystectomy	158
References	159
21 Preventative Measures for Those with High Risk MIBC	161
21.1 Mediterranean Diet and Bladder Cancer Risk	161
21.2 Risk Factors in Bladder Cancer: Preventative Measures	161
21.3 Preventative Measures in Bladder Cancer: Impact of Vitamin A	162
21.4 Prevention of Bladder Cancer: Fluid Intake	162
21.5 Mitomycin and BCG in Bladder Cancer Prevention	162
21.6 Preventative Measures and Urethral Recurrence	163
21.7 BCG in Intermediate and High-Risk Disease	163
References	163
22 Bladder Cancer Risk Post Pelvic Irradiation	165
22.1 Radiation Induced Bladder Cancer Post Cervical Cancer	165
22.2 Clinical Presentation of Bladder Cancer Post-pelvic Irradiation	165
22.3 Survival Outcomes in Bladder Cancer Post Pelvic Irradiation	166
22.4 Prior Irradiation for Prostate Cancer and Risk of Bladder Cancer	166
22.5 Management of Pelvic Irradiation Induced Bladder Cancer	166
References	167
Part V Management of MIBC	
23 A Systematic Review on Bladder Preservation Strategies and MIBC	171
23.1 Research Methods	171
23.2 Systematic Review Results	173

23.2.1	Tetramodal Bladder Preservation Therapy	173
23.2.2	Radical Cystectomy vs. Bladder Preservation in the Elderly	173
23.2.3	Bladder Perseveration with Brachytherapy and External Beam Radiotherapy	173
23.2.4	Survival Outcomes in Bladder Preservation Therapy for MIBC	174
23.2.5	Patterns of Bladder Preservation Therapy	174
23.2.6	Bladder Preservation Rate	174
23.2.7	Paclitaxel, Trasuzumab with Irradiation After Transurethral Surgery	175
23.2.8	Second TURBT in Bladder Preservation for MIBC	175
23.2.9	Trimodal Chemotherapy with Cisplatin in Bladder Preservation	175
23.2.10	Grey Matter Relating to Systematic Review	176
	References	176
24	Partial Cystectomy	179
24.1	Predictive Factors in Partial Cystectomy	179
24.2	Partial Cystectomy Rate	179
24.3	Molecular Markers Allow Prediction of Survival in Bladder Preservation Strategies	180
24.4	Oncological Outcomes in Partial Cystectomy	180
	References	181
25	Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer	183
25.1	Health Related Quality of Life in the Elderly with Radical Cystectomies	184
25.2	Bladder Preservation Therapy in the Elderly	185
25.3	Radiotherapy in Elderly Patients with MIBC	185
25.4	Grey Literature	186
	References	186
26	Muscle Invasive Bladder Cancer and Neoadjuvant Chemotherapy	189
26.1	The Rationale for Neoadjuvant Chemotherapy	189
26.2	Neoadjuvant Chemotherapy: Clinical Effectiveness	190
26.3	Meta-Analyses for Neoadjuvant Chemotherapy	191
26.4	Disadvantages of Neoadjuvant Chemotherapy	191
26.5	Targeted Therapies and Bladder Preservation	192
26.6	Evaluation of ‘QUALYs’	192
26.7	Benefits vs. Risks of Neoadjuvant Chemotherapy	192
26.8	Controversies in Clinical Effectiveness of Neoadjuvant Chemotherapy	193
	References	194

27 Trimodal Therapy in Bladder Cancer	197
References	199
28 Trimodal Therapy: A Systematic Review—Is It Really Better than Radical Therapy?	201
28.1 Trimodal Chemotherapy	202
28.2 Efficacy of 5FU as Part of Trimodal Therapy	203
28.3 Outcomes from Trimodal Therapy for MIBC	203
28.4 Trimodal Therapy in the Elderly	206
28.5 Trimodal Therapy and Radical Cystectomy	206
28.6 Proton Beam Therapy in Trimodal Therapy	207
28.7 Reviews Related to Trimodal Therapy for MIBC	207
References	209
Part VI Radical Cystectomy	
29 Radical Cystectomy Outcomes	213
References	214
30 Laparoscopic vs. Open vs. Robotic Cystectomy	217
References	219
31 A Systematic Review on Radical Cystectomy: Laparoscopic vs. Open vs. Robotic	221
31.1 Research Methods	221
31.2 Complication Rate Robotic vs. Open Cystectomy	223
31.3 Laparoscopic vs. Open Radical Cystectomy with Prior Abdominal Surgery	224
31.4 Laparoscopic vs. Open Cystectomy Outcomes	225
31.5 Robotic Cystectomy vs. Laparoscopic Cystectomy Outcomes	225
31.6 Recurrence After Open and Robotic Radical Cystectomy	225
31.7 Robotic vs. Laparoscopic Radical Cystectomy in Elderly Patients	226
31.8 Robotic vs. Laparoscopic High Extended Pelvic Lymph Node Dissection	226
31.9 Open vs. Laparoscopic vs. Robotic Cystectomy	226
References	227
32 Prostate Sparing Cystectomy: A Systematic Review	229
32.1 Research Methods	229
32.2 Systematic Review: Results	231
32.2.1 A Modification of Technique: Prostate Sparing Cystectomy	231
32.2.2 Seminal Sparing Cystectomy	231
32.2.3 Oncological Outcomes of Prostate Sparing Cystectomy	232
32.2.4 Risk of Prostate/Urothelial Cancer in Prostate Sparing Cystectomy	233

32.2.5	Functional Outcomes Post Prostate Sparing Cystectomy	234
32.2.6	Erectile Function after Prostate Sparing Cystectomy	235
32.2.7	Post-operative Complications After Prostate Sparing Cystectomy	236
32.2.8	Grey Literature Relating to Systematic Review	237
	References	237
33	A Systematic Review on Nerve Sparing Cystoprostectomy	241
33.1	Research Methods	241
33.2	Outcomes of Nerve-Sparing in Radical Cystectomy	243
33.3	Post-operative Complications in Nerve Sparing Prostatectomy	243
33.4	Radical Cystectomy and Nerve Sparing in Women	244
33.5	Nerve Sparing in Either Gender	244
33.6	Nerve Sparing Radical Cystectomy and Impact on Continence	244
33.7	Nerve Sparing Cystectomy and Impact on Orthotopic Neobladder	245
33.8	Prostate Sparing vs. Nerve Sparing Cystectomy	245
33.9	Outcomes in Nerve Sparing Cystectomy	246
33.10	Penile Rehabilitation in Cystoprostectomy	246
33.11	High Risk Bladder Cancer and Nerve Sparing Radical Cystectomy	247
	References	247
34	Robotic Radical Cystectomy and Lymph Node Dissection: What Are the New Ways Forward?	249
	References	250
35	A Systematic Review on RARC and LND	253
35.1	Research Methods	253
35.2	Robotic RARC and LND	255
35.3	Post-operative Complications from LND	255
35.4	Extended Pelvic Lymphadenopathy in RARC	255
35.5	Standard Lymphadenectomy in RARC	256
35.6	Robotic Lymphadenectomy with the Da Vinci S	256
35.7	Robotic vs. Open Lymphadenectomy	257
35.8	Robotic vs. Laparoscopic Lymphadenectomy for Radical Cystectomy	258
35.9	Grey Literature Relating to Review	258
	References	258
36	Robotic Cystectomy and Sentinel Node Mapping	261
	References	262
37	MIBC and Radical Cystectomy in the Elderly: A Systematic Review	263
37.1	Research Methods	263
37.2	Systematic Review Results	265

37.2.1	Prognostic Factors in Elderly Patients	265
37.2.2	Mortality Rate in Elderly undergoing Cystectomy	265
37.2.3	Type of Reconstruction in the Elderly	267
37.2.4	Open Radical Cystectomy	268
37.2.5	Laparoscopic Radical Series in Elderly	268
37.2.6	National Trends in Cystectomy Figures for the Elderly	268
37.2.7	Robotic vs. Open Radical Cystectomy in Elderly	269
37.2.8	Extraperitoneal vs. Transperitoneal Laparoscopic Approaches	269
37.2.9	Younger vs. Older Patients for Radical Cystectomy	269
37.2.10	Risks and Benefits of Pelvic Lymphadenectomy in the Elderly	270
37.2.11	Outcomes in Elderly Patients	270
37.2.12	Pathology of Elderly Patients Undergoing Radical Cystectomy	271
37.2.13	Post-operative Outcomes in Younger and Older Patients	271
37.2.14	Survival Benefit Younger vs. Older Patients: Radical Cystectomy	272
	References	273
38	Female Outcomes in Bladder Cancer	275
38.1	Research Methods	275
38.2	Prognostic Factors in Female Bladder Cancer	277
38.3	Postoperative Complications in Female Gender for Cystectomy	278
38.4	Survival Outcomes in Female Bladder Cancer	278
38.5	Urethral Sparing Cystectomy	280
38.6	Survival Outcomes in T4 Bladder Cancer in Females	280
38.7	Health Related Quality of Life in Female Patients Post Radical Cystectomy	281
38.8	Urethral Recurrence in Female Bladder Cancer	281
38.9	Female Sexual Dysfunction After Radical Cystectomy and Neobladder Construction	282
38.10	Reviews Related to the Systematic Review	282
	References	283
Part VII Radical Radiotherapy		
39	MIBC Radical Radiotherapy	287
39.1	Research Methods	287
39.2	Overall Survival for Radical Radiotherapy	289
39.3	Chemoradiation vs. Radical Cystectomy for MIBC	289
39.4	Trimodal Therapy vs. Cystectomy	289
39.5	Radiochemotherapy vs. Radical Cystectomy	290

39.6	Radiochemotherapy in the Elderly	291
39.7	GU Toxicity from Radical Radiotherapy	292
39.8	Grey Matter	292
	References	293
40	The Robotic Approach to Redo Surgery	295
	References	296
41	Secondary Pelvic Malignancies and Bladder Cancer	297
	References	298
42	Robotic Radical Cystectomy: Technical Tips and Tricks	299
	References	301
43	A Focus on Robotic Intracorporeal Neobladder Formation	303
	References	304
44	Orthotopic Neobladders vs. Ileal Conduits	305
	References	306
45	The Role of Enhanced Recovery in Robotic Cystectomy	307
	References	308
46	MIBC: Quality of Life with Urinary Diversion	309
	References	311
47	MIBC: Orthotopic vs Ileal Conduit, Which Is Better?	313
	References	314
48	MIBC: A Systematic Review on Orthotopic Neobladder vs. Ileal Conduit, Which Is Better?	317
48.1	Incidence of Ileal Conduit vs. Orthotopic	318
48.2	Health Related Quality of Life	319
48.3	Morbidity and Mortality	320
48.4	AKI	320
48.5	Modified S Pouch Outcomes	321
48.6	Conversion Factors	321
48.7	Factors Influencing Selection of Urinary Diversion	322
48.8	Types of Diversion Outcomes	322
48.9	Systematic Reviews Relating to Urinary Diversion	322
	References	323
49	Urinary Diversion Ileal Conduit vs. Studer vs. Catherisable Stoma	325
49.1	Research Methods	325
49.2	T-Pouch Neobladder vs. Studer Pouch	327
49.3	Studer Pouch vs. I Pouch	327
49.4	The Studer Neobladder	328
49.5	Ileal Conduit vs. Neobladder	329
	References	329

50	Robotic Cystectomy and Intracorporeal Stoma Formation:	
	Robotic Management of Ureteric Strictures	331
	References	332
51	Management of Ureteric Stricture Disease Post Urinary Diversion in Bladder Cancer	333
51.1	Systematic Review Results	335
51.1.1	Ureteric Stricture Rates Post Radical Cystectomy: Ileal Conduit vs. Orthotopic Neobladder	335
51.1.2	Rates of Ureteric Strictures: Open vs. Robotic Radical Cystectomy	335
51.1.3	New Techniques in Management of Ureteric Strictures	335
51.1.4	Ureteric Stricture Rate: Wallace vs. Bricker Anastomosis	336
51.1.5	Continuous vs. Interrupted Suture Impact on Ureteric Stricture Rate	337
51.1.6	Use of Ureteric Stents and Impact on Ureteric Stricture Rates	337
51.1.7	Impact of Prior Pelvic Irradiation On Ureteric Strictures	337
51.1.8	Development of Malignant Ureteric Strictures vs. Benign Strictures	338
51.1.9	Risk Factors for Development of Ureteric Strictures	338
51.1.10	Endoureterotomy vs. Open Surgical Revision for Ureteric Strictures	338
51.1.11	Risk of Ureteric Obstruction with Antireflux Techniques in Orthotopic Neobladders	339
51.1.12	Balloon Dilation in Ureterointestinal Anastomotic Stricture	340
	References	340
52	Neoadjuvant Chemotherapy vs. Radical Cystectomy in Muscle Invasive Bladder Cancer	343
52.1	Systematic Review Results	345
52.1.1	Neoadjuvant Chemotherapy vs. Radical Cystectomy Alone in Muscle Invasive Bladder Cancer	345
52.1.2	MVAC in Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	345
52.1.3	MVAC vs. Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy	345
52.1.4	Impact of Cisplatin Neoadjuvant Chemotherapy on Muscle Invasive Bladder Cancer Outcomes	346
52.1.5	Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	347

52.1.6	Gemcitabine Plus Carboplatin as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	347
52.1.7	Predictors of Response in Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.	347
52.1.8	Gemcitabine, Cisplatin and Lapatinib as Neoadjuvant Chemotherapy.	349
52.1.9	Erlotinib as Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer.	349
52.1.10	Imaging to Assess Response of Muscle Invasive Bladder Cancer to Neoadjuvant Chemotherapy	349
52.1.11	Complications from Neoadjuvant Chemotherapy	350
52.1.12	Survival Outcomes in Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer	351
52.1.13	Pathological Impact of Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	352
52.1.14	Impact of Suboptimal Neoadjuvant Chemotherapy Dosing on Outcomes in Muscle Invasive Bladder Cancer .	353
52.1.15	Neoadjuvant Chemotherapy in Radical Cystectomy vs. Radiotherapy.	353
52.1.16	Neoadjuvant Chemotherapy in a Salvage Cystectomy Setting.	354
52.1.17	Neoadjuvant Chemotherapy vs. Active Surveillance in Muscle Invasive Bladder Cancer	354
52.1.18	Systematic Reviews Relating to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	354
	References.	355
53	Radical Cystectomy and Renal Transplant	359
53.1	Research Methods	359
53.2	Risk of Bladder Cancer in Renal Transplant Patients	361
53.3	Risk and Safety of Radical Cystectomy in the Renal Transplant Patient.	361
53.4	Risk According to Type of Urinary Diversion	361
53.5	Difficulties Encountered in Renal Transplant Patients	362
53.6	A New Technique of Robotic Cystectomy for Renal Transplant Patients.	362
53.7	Surgical Technique in Renal Transplant Patients.	363
53.8	BCG vs. MMC in Bladder Cancer.	363
53.9	Histological Variants in the Renal Transplant Patient	364
53.10	Presentation and Management of Bladder Cancer in the Renal Transplant Population	364
53.11	Orthotopic Neobladders in the Renal Transplant Population	365
53.12	Transplant Post Cystectomy and Urinary Diversion	366
53.13	Post-operative Complications Post Radical Cystectomy	366
53.14	Impact of CKD on Oncological Outcomes in MIBC.	366

53.15	Reviews Related to Systematic Review.....	367
	References.....	367
54	Radical Cystectomy and Acute Renal Failure	369
54.1	AKI Post Major Surgery	370
54.2	Risk Factors for AKI After Radical Cystectomy	371
54.3	Impact of AKI Post Radical Cystectomy on CKD.....	371
54.4	Radical Cystectomy with ARF Caused by Rhabdomyolysis.....	372
54.5	Radical Cystectomy, AKI and Association with Uric Acid	372
54.6	Radical Cystectomy: Ileal Conduit vs. Neobladder and AKI	373
54.7	Use of Noradrenaline and Risk of Acute Renal Failure in Radical Cystectomy	373
54.8	Radical Cystectomy, Neoadjuvant Chemotherapy and AKI	374
55	A Systematic Review on Bladder Cancer, Radical Cystectomy and Complications	375
55.1	Research Methods	375
55.2	Impact of Type of Urinary Diversion on Complications	377
55.3	Perioperative Complications for Robotic Radical Cystectomy and Intracorporeal Urinary Diversion	377
55.4	Ileal Conduit vs. Orthotopic Neobladder Complication Rate	378
55.5	Complications in Ileal Conduit Diversion	379
55.6	Risk Factors for Complications Post Radical Cystectomy for Bladder Cancer.....	379
55.7	Complication by Urinary Diversion Type	380
55.8	Preoperative Anaemia and Impact on Post-operative Complications in Radical Cystectomy.....	381
55.9	Complications Post Radical Cystectomy Using a Standardised Reporting System.....	381
55.10	Complications Post Orthotopic Neobladders.....	382
55.11	Complications Post Laparoscopic Radical Cystectomy	383
55.12	Post-operative Complications of Radical Cystectomy in the Elderly	383
55.13	Complications of Radical Cystectomy Post Prior Radiotherapy	384
55.14	Impact of Metabolic Syndrome on Radical Cystectomy	385
55.15	Mortality Rate and Urinary Diversion	385
	References.....	386

Part VIII Patient Fitness, CPEX Testing and Enhanced Recovery

56	Physical Pre-habilitation Prior to Radical Cystectomy.....	391
	References.....	392
57	Exercise Therapy Pre-surgery	393
	Reference	393

58	Patient Fitness for Surgery.....	395
	References.....	396
59	Systematic Review on Enhanced Recovery and Radical Cystectomy.....	397
59.1	Research Methods	397
59.2	ERAS vs. Standard Care Post Radical Cystectomy.....	399
59.3	Adherence to ERAS Protocols.....	399
59.4	Readmission Rates for ERAS	399
59.5	Surgical Approach and the Impact of ERUS	400
59.6	Impact of ERAS on Post-operative Recovery	400
59.7	Patient Nonmodifiable Factors Predictive of ERAS Outcomes	401
59.8	Impact of ERAS on Post-operative Complications	401
59.9	Impact of ERAS on Hospital Stay.....	402
59.10	Impact of Type of Fluid on ERAS	402
59.11	Impact of Multidisciplinary Care on ERAS Outcomes	403
59.12	Impact of PROMS on ERAS	403
59.13	Impact of ERAS on Lymphadenectomy	403
59.14	Pain Relief and ERAS After Radical Cystectomy.....	404
59.15	Impact of ERAS on Intracorporeal Urinary Diversion	404
59.16	Prognostic Factors for ITU Admission in ERAS.....	404
59.17	Grey Matter: ERAS vs. Standard Care for Radical Cystectomy ..	405
	References.....	405
60	Cardio-Pulmonary Exercise Testing and Major Urological Surgery: Risk Stratification and Preoperative Assessment.....	407
60.1	Cardiopulmonary Exercise Testing	407
60.2	Other Methods of Assessment	408
60.3	Search Strategy	408
60.4	Systematic Review Results	409
60.4.1	CPEX and Major Surgery: The Research So Far	409
60.4.2	Future Research: Evaluation of CPEX	410
	References.....	410
61	Robotic Radical Cystectomy and Enhanced Recovery: An Evolving Care Pathway	413
	References.....	414
62	Robotic Radical Cystectomy and Intracorporeal Stoma Formation: A New Technology to Guide Resection	417
	References.....	418
63	A Systematic Review on Obesity in Bladder Cancer.....	419
63.1	Systematic Review Results on Obesity in Bladder Cancer	420
63.1.1	Impact of BMI on MIBC and Radical Cystectomy Outcomes	420
63.1.2	Impact of BMI on Mortality After Radical Cystectomy ..	421

63.1.3	Impact of BMI on Recurrence and Progression of Bladder Cancer: High Grade None Muscle Invasive Disease	422
63.1.4	BMI and Risk of Recurrence in NMI Bladder Cancer	422
63.1.5	Obesity and Risk of Bladder Cancer	423
63.1.6	BMI and Prognosis in MIBC	424
63.1.7	Reviews on BMI and Bladder Cancer	424
	References.	425

Part IX New Techniques in Management of Muscle Invasive Bladder Cancer

64	A Systematic Review on Immunotherapy in Locally Advanced and Metastatic Bladder Cancer	429
64.1	Systematic Review Results	431
64.1.1	Pembrolizumab and Radiotherapy in Bladder Cancer	431
64.1.2	Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma	431
64.1.3	Adjuvant Bestatin Immunotherapy and Radical Radiotherapy in Bladder Cancer	431
64.1.4	Predictors of Response to Immunotherapy	432
64.1.5	Markers of Response to Immunotherapy	432
64.1.6	A Normogram Predicting Survival from Immunotherapy in Locally Advanced and Metastatic Bladder Cancer	432
64.1.7	Infusion of Autologous T Helper Cells in Metastatic Bladder Cancer	433
64.1.8	Consensus Guidelines on Immunotherapy in Locally Advanced and Metastatic Bladder Cancer	433
	References.	433
65	The Role of Immune Checkpoint Inhibitors in Bladder Cancer	435
65.1	Systematic Review Results	437
65.1.1	Pd-L1 Expression in Bladder Cancer	437
65.1.2	Anti-PD-L1 and Radiotherapy	439
65.1.3	Immune Checkpoint Inhibition in Variant Histology in Bladder Cancer	439
65.1.4	Ramucirumab and Docetaxel vs. Placebo in Bladder Cancer	440
65.1.5	T-Cell Immunoglobulin Mucin-3 Expression in Bladder Cancer	441
65.1.6	Inhibition of G9a/DNMT and Immune-Mediated Bladder Cancer Regression	441
65.1.7	Inhibition of PI3K Pathway Increases Immune Infiltrate in Muscle-Invasive Bladder Cancer	441
65.1.8	Neoantigen-Reactive Tumour-Infiltrating Lymphocytes in Bladder Cancer	442

65.1.9	Response Rate to Chemotherapy after Immune Checkpoint Inhibition in Metastatic Urothelial Cancer	442
	References	442
66	The Role of Chemotherapy in Locally Advanced and Metastatic Bladder Cancer	445
66.1	Systematic Review Results	447
66.1.1	Cis-Diamminedichloroplatinum in Locally Advanced and Metastatic Bladder Cancer	447
66.1.2	Gemcitabine in Locally Advanced and Metastatic Bladder Cancer	447
66.1.3	Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer	447
66.1.4	Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer	448
66.1.5	Gemcitabine and Cisplatin vs. Carboplatin and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer	448
66.1.6	Paclitaxel, Cisplatin and Gemcitabine vs. Gemcitabine and Cisplatin	448
66.1.7	Gemcitabine and Irinotecan in Locally Advanced and Metastatic Bladder Cancer	449
66.1.8	Carboplatin Based Chemotherapy for Locally Advanced and Metastatic Bladder Cancer	449
66.1.9	Gemcitabine vs. Oxaliplatin for Locally Advanced and Metastatic Bladder Cancer	450
66.1.10	Paclitaxel in Locally Advanced and Metastatic Bladder Cancer	450
66.1.11	Neoadjuvant Cisplatin, Methotrexate and Vinblastine in Locally Advanced and Metastatic Bladder Cancer	450
66.1.12	Larotaxel and Cisplatin vs. Gemcitabine and Cisplatin for Locally Advanced or Metastatic Bladder Cancer	451
66.1.13	Mocetinostat in Locally Advanced and Metastatic Bladder Cancer	451
66.1.14	Gemcitabine and Cisplatin vs. Methotrexate, Vinblastine, Doxorubicin and Cisplatin for Locally Advanced and Muscle Invasive Bladder Cancer	452
66.1.15	Gemcitabine, Cisplatin and Sorafenib vs. Chemotherapy Alone in Locally Advanced and Metastatic Bladder Cancer	453
66.1.16	Adjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer	454
66.1.17	Gemcitabine and Cisplatin in Renal Dysfunction for Locally Advanced and Metastatic Bladder Cancer	454

66.1.18 Paclitaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer	454
66.1.19 Paclitaxel, Gemcitabine and Cisplatin in Locally Advanced and Metastatic Bladder Cancer	454
66.1.20 Paclitaxel, Gemcitabine and Carboplatin in Locally Advanced and Metastatic Bladder Cancer	455
66.1.21 Paclitaxel in Platin Refractory Locally Advanced and Metastatic Bladder Cancer.	455
66.1.22 Docetaxel in Locally Advanced and Metastatic Bladder Cancer.	456
66.1.23 Docetaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer.	456
66.1.24 Cabizataxel vs. Vinflunine in Locally Advanced and Metastatic Bladder Cancer	457
66.1.25 Cisplatin, Epirubicin, Methotrexate in Locally Advanced and Metastatic Bladder Cancer	457
66.1.26 Methotrexate, Carboplatin, Mitoxantrone and Vincristine in Locally Advanced and Metastatic Bladder Cancer.	458
66.1.27 Methotrexate, Paclitaxel, Epirubicin and Carboplatin in Advanced Bladder Cancer	458
66.1.28 Methotrexate, Carboplatin and Vinblastine in Locally Advanced and Metastatic Bladder Cancer	458
66.1.29 Methotrexate, Carboplatin, Vinblastine and Epirubicin in Locally Advanced and Metastatic Bladder Cancer.	459
66.1.30 Gemcitabine, Cisplatin and Docetaxel in Locally Advanced and Metastatic Bladder Cancer.	459
66.1.31 Everolimus in Locally Advanced and Metastatic Bladder Cancer	460
66.1.32 Doxorubicin and Gemcitabine Followed by Isofostamide, Paclitaxel, and Cisplatin in Locally Advanced and Metastatic Bladder Cancer	460
66.1.33 Pemetrexed and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer.	461
66.1.34 Paclitaxel and Gemcitabine in Locally Advanced and Metastatic Bladder Cancer.	461
66.1.35 Cisplatin, Epirubicin and Docetaxel in Locally Advanced and Metastatic Bladder Cancer	461
66.1.36 Vinflunine in Locally Advanced and Metastatic Bladder Cancer	462
66.1.37 Doxorubicin in Locally Advanced and Metastatic Bladder Cancer	462
References.	463

67	Chemo-radiation in Muscle Invasive Bladder Cancer	467
67.1	Systematic Review Methods	467
67.2	Systematic Review Results	469
67.2.1	Radical Cystectomy vs. Chemoradiation in Muscle Invasive Bladder Cancer	469
67.2.2	Predictors of Response to Chemoradiation in Bladder Preservation Therapy	471
67.2.3	Biochemical Markers of Response to Chemoradiation Therapy in Muscle Invasive Bladder Cancer	472
67.2.4	Alternative Regimes in Chemoradiation for Muscle Invasive Bladder Cancer	476
67.2.5	Outcomes from Chemoradiation in Muscle Invasive Bladder Cancer	478
67.2.6	Low Dose Chemoradiotherapy Outcomes in Muscle Invasive Bladder Cancer	481
67.2.7	Chemotherapy vs. Chemoradiotherapy Outcomes in Muscle Invasive Bladder Cancer	483
67.2.8	The Role of Neoadjuvant Chemotherapy Pre Chemoradiation	483
67.2.9	Neoadjuvant Chemotherapy vs. Concomitant Chemoradiation for Muscle Invasive Bladder Cancer	484
67.2.10	Chemoradiation in the Elderly or Unfit with Muscle Invasive Bladder Cancer	484
67.2.11	Female Outcomes with Chemoradiotherapy in Muscle Invasive Bladder Cancer	486
67.2.12	Patient Reported Outcome Measures in Chemoradiation Therapy	486
67.2.13	Adjuvant Chemotherapy vs. Chemoradiotherapy for Muscle Invasive Bladder Cancer	487
67.2.14	Chemoradiation in Advanced Bladder Cancer	487
67.2.15	Side Effects of Chemoradiotherapy in Muscle Invasive Bladder Cancer	487
67.2.16	Chemoradiation in Whole Bladder vs. Partial Bladder Treatment	488
67.2.17	Mortality Outcomes in Chemoradiotherapy for Muscle Invasive Bladder Cancer	488
67.2.18	International Reviews and Guidelines on Chemoradiation in Muscle Invasive Bladder Cancer	489
	References	490
68	Trials in Localized Bladder Cancer	495
68.1	Systematic Review Results	496
68.1.1	Bladder Preservation Therapy	496
68.1.2	Pre-operative Fitness	497
68.1.3	Partial Cystectomy	498

68.1.4	Open vs. Robotic Radical Cystectomy	498
68.1.5	Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer	500
68.1.6	Extended vs. Limited Lymph Node Dissection in Radical Cystectomy	501
68.1.7	Sentinel Node Detection in Muscle Invasive Bladder Cancer	501
68.1.8	Urinary Diversion Post Radical Cystectomy	501
68.1.9	ERAS in Radical Cystectomy	502
68.1.10	Radiotherapy in Muscle Invasive Bladder Cancer	502
68.1.11	Chemoradiotherapy in Muscle Invasive Bladder Cancer	502
68.1.12	Brachytherapy in Muscle Invasive Bladder Cancer	503
	References	503
69	Trials in Locally Advanced and Metastatic Bladder Cancer	507
69.1	Systematic Review Results	509
69.1.1	Adjuvant Chemoradiation vs. Chemotherapy Alone in Locally Advanced Bladder Cancer	509
69.1.2	Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer	509
69.1.3	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer	509
69.1.4	Immunotherapy in Locally Advanced and Metastatic Bladder Cancer	513
69.1.5	Immunotherapy and Radiotherapy in Metastatic Bladder Cancer	515
69.1.6	Chemoradiotherapy in the Elderly	515
	References	515
Part X Salvage Therapy		
70	A Systematic Review on Salvage Cystectomy	521
70.1	Research Methods	521
70.2	Is Salvage Cystectomy Required?	523
70.3	Survival Outcomes in Salvage Cystectomy	523
70.4	Salvage Cystectomy After EBRT	524
70.5	Prognostic Factors in Salvage Cystectomy	525
70.6	Post Operative Complications for Salvage Cystectomy	526
70.7	Salvage Cystectomy and Orthotopic Neobladder	527
	References	527
Part XI Bladder Cancer Survivorship		
71	Bladder Cancer Survivorship	531
71.1	Systematic Review	533

71.1.1	Survivorship Differences in Demographic Factors	533
71.1.2	Health Related Quality of Life	533
71.1.3	Unmet Informational Needs in Bladder Cancer Survivorship	534
71.1.4	Exercise Programming and Counselling in Bladder Cancer Survivorship	534
71.1.5	Health Behaviours in Bladder Cancer Survivorship	534
71.1.6	Survivorship Care Plans	535
71.1.7	Physical Prehabilitation Prior to Cystectomy	535
	References	535
72	Support for Partners in Bladder Cancer	537
	References	540
73	Muscle Invasive Bladder Cancer: What is the Impact of Radical Cystectomy on Patient Reported Outcome Measures?	541
73.1	Definition of Bladder Cancer Survivorship	541
73.2	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 1 Erectile Dysfunction	541
73.3	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 2 Age Related disease	542
73.4	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 3 Side Effects Post Operatively	543
73.5	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 4 Psychological Impact	544
73.6	Bladder Cancer Survivorship and Patient Reported Outcome Measures: Code 5 Impact of Operation on General Health	544
	References	545
74	Survivorship Issues in Muscle Invasive Bladder Cancer	547
	References	549
75	Muscle Invasive Bladder Cancer and Health Related Quality of Life	551
	References	552
76	Body Image in Bladder Cancer	555
	References	557
77	Psychological Impact in Bladder Cancer	559
77.1	Systematic Review Results	561
77.1.1	Psychological Impairment in Patients Referred for Bladder Cancer Investigations	561
77.1.2	Psychological Distress and Radical Cystectomy	561
77.1.3	Psychological Distress in Smokers with Bladder Cancer	562
77.1.4	Psychological Impact of Type of Urinary Diversion	562

77.1.5	Quality of Life During Chemotherapy or Immunotherapy in Bladder Cancer.....	563
77.1.6	Psychological Issues in Metastatic Bladder Cancer.....	563
	References.....	564
Part XII Palliative Therapy in Muscle Invasive Bladder Cancer		
78	The Role of Palliative Cystectomy in Bladder Cancer	567
78.1	Research Methods	567
78.2	Systematic Review Results	569
78.2.1	Lymph Node Positive Bladder Cancer and Outcomes with Cystectomy	569
78.2.2	Outcomes from Palliative Cystectomy.....	570
78.2.3	Outcomes from Palliative Robotic Cystectomy	570
78.2.4	Systematic Reviews Relating to Palliative Cystectomy.....	571
	References.....	571
79	Palliative Care in Bladder Cancer.....	573
79.1	Systematic Review Results	575
79.1.1	Surgery in Palliation	575
79.1.2	Patient Selection in Palliative Radiotherapy.....	575
79.1.3	Palliative Chemotherapy in Muscle Invasive Bladder Cancer.....	576
	References.....	577
Index		579